Roche's Tecentriq Improves Survival in NSCLC Patients Ineligible for Platinum Chemo

Roche’s Tecentriq has been shown to improve survival in non-small cell lung cancer (NSCLC) patients who are not eligible for platinum-based doublet chemotherapy, according to data from the Phase III IPSOS trial. The study, led by University College London (UCL) and supported by Roche, revealed its findings in The Lancet. The results showed that patients treated with Tecentriq had a median overal..